Conference abstract · 27 Jul 2015
Conference abstract
Regulatory transparency: Key aspects throughout access BA/BE report
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Brazil is the 5th biggest pharmaceutical market in the world, and the Brazilian Heath Surveillance Agency (ANVISA) is responsible to evaluate the products quality and safety. Hence, in the field of health regulation, the wide access to data of drugs and related technical documents, especially BA/BE report data, is in expansion at FDA, EMA and ANVISA. A fact to be evaluated is how disclosure policies are built, emphasizing the regulatory impact analysis and detecting the risks and benefits involved. Bioavailability and Bioequivalence Studies (BA/BE) is essentially significant as contain vital information regard drug variability and pharmacokinetic profile over and above is the primary source of information about product efficacy (Generics or multisource products). Discussion: Actually the Brazilian Electronic Database (Sineb) has more than 2000 BA/BE reports of which 30% had negative results, but none of these trials are available for public consultation. Around 300 studies were pilots, performed in order to gain knowledge (Pharmacodynamics/Pharmacokinetic) about the API (Active Product Ingredient). The openness will enable public scrutiny and secondary analysis probably resulting in improvement of the products quality and public health development as well as the social accountability. Over and above the reanalysis will reinforce confidence over Agency´s skills, in the other hand inappropriate reanalysis or methodologically flawed can mislead treatment adherence or public health programs. Conclusion: Responsible public disclosure of BABE reports lead to improve the common knowledge about API characteristics avoiding unnecessary studies as well as protecting voluntaries integrity. However, some boundaries should be respected in order to not frustrate investments on bio-pharmaceutical research and development (R&D) along with not to bias the Agency’s decisionmaking process. After all, decreasing the number of tests imply lowering the registers costs. PDF HTML
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 Sep 2014
Regulatory transparency: Technical, legal and ethical aspects of access to regulatory applications (medicines dossier) - Brazilian approach
Commentary · 29 Nov 2025
FDA Regulatory Evolution: Faster Access, Safer Drugs
Short communication · 30 Nov 2024
Unpacking the Role of Regulatory Affairs in Ensuring Affordable Access to New Drugs
Opinion · 27 Sep 2024
The Role of Regulatory Affairs in Product Approval and Market Access
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Varley Dias Sousa”
- BylineArticles whose byline prints “Damaris Silveira”
